Abstract:

Sclerostin is a glycoprotein encoding by SOST gene and can bind to Lrp4/5/6 receptor to block the Wnt signaling pathway, so as to regulate the bone metabolism. Mutations of the SOST gene are relevant to osterporosis and autosomal dominant diseases such as sclerosteosis, Van Buchem disease, and craniodiaphyseal dysplasia. Recent studies have confirmed that sclerostin can not only block the differentiation of osteoblast to inhibit bone formation by various ways, but also have a catabolic action through promotion of osteoclast formation and activation of osteocytes in a RANKL-dependent manner. The sclerostin monoclonal antibody may bring a new way for the treatment of osteoporosis. Currently, the clinical test is underway. The safety and validity of sclerostin monoclonal antibody need to be further researched.

Key words: sclerostin, bone metabolism, Wnt signaling pathway, osteoporosis